Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

NEW YORK, Feb. 26, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results for the year ended December 31, 2020 and highlighted recent activity.
“2020 was a year marked by significant operational and clinical milestone achievements across our pipeline, culminating most recently in two important data readouts…

Click here to view the original article.